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Abstract
Incorporation of imatinib into chemotherapeutic regimens has improved the
prognosis of children with Philadelphia chromosome-positive acute lymphoblas-
tic leukemia (Ph+ALL). We investigated a role of imatinib immediately before
hematopoietic stem cell transplantation (HSCT). Children with Ph+ALL were
enrolled on JPLSG Ph+ALL 04 Study within 1 week of initiation of treatment for
ALL. Treatment regimen consisted of Induction phase, Consolidation phase,
Reinduction phase, 2 weeks of imatinib monotherapy phase, and HSCT phase
(Etoposide+CY+TBI conditioning). Minimal residual disease (MRD), the
amount of BCR–ABL transcripts, was measured with the real-time PCR method.
The study was registered in UMIN-CTR: UMIN ID C000000290. Forty-two
patients were registered and 36 patients (86%) achieved complete remission
(CR). Eight of 17 patients (47%) who had detectable MRD at the beginning of
imatinib monotherapy phase showed disappearance or decrease in MRD after
imatinib treatment. Consequently, 26 patients received HSCT in the first CR and
all the patients had engraftment and no patients died because of complications of
HSCT. The 4-year event-free survival rates and overall survival rates among all
the 42 patients were 54.1  7.8% and 78.1  6.5%, respectively. Four of six
patients who did achieve CR and three of six who relapsed before HSCT were sal-
vaged with imatinib-containing chemotherapy and subsequently treated with
HSCT. The survival rate was excellent in this study although all patients received
HSCT. A longer use of imatinib concurrently with chemotherapy should elimi-
nate HSCT in a subset of patients with a rapid clearance of the disease.
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Progress in childhood leukemia treatment has raised the
5-year survival rate to as high as 80–90%, however, out-
comes in Philadelphia chromosome-positive acute lym-
phoblastic leukemia (Ph+ALL) patients still remain poor
[1, 2]. Arico et al. reported results of an international ret-
rospective study comprising 610 Ph+ALL children treated
with intensive chemotherapy without tyrosine-kinase
inhibitors and observed 7-year event-free survival (EFS)
and overall survival (OS) to be 32% was 45%, respectively
[3]. They also showed that allogeneic hematopoietic stem
cell transplantation (HSCT) was beneficial. In another
study which was the first large prospective cohort study
of pediatric patients treated with chemotherapy and tyro-
sine-kinase inhibitor (TKI), the Children’s Oncology
Group (COG) assessed increased exposure to imatinib
combined with chemotherapy in five cohorts [4]. Forty-
four children, who received continuous imatinib from
consolidation to the end of treatment, had 3-year EFS of
80%. In this group, which excluded patients with induc-
tion failure, the outcome of children treated with HSCT
was not better than those treated with chemotherapy plus
imatinib. The excellent outcome of this cohort of patients
was recently updated: 5-year EFS of 28 patients treated
with chemotherapy alone was 70% [5]. Results of an
additional study were recently reported by the European
intergroup study (EsPhALL) [6]. They adopted a risk-
stratified approach for treatment of patients on the basis
of early response to therapy and found that the combina-
tion of imatinib and Berlin-Frankfurt-Munster (BFM)
backbone intensive treatment was safe and possibly bene-
ficial to patients, although 77% received HSCT.
While results of these previous reports showed overall
improved outcomes associated with imatinib plus inten-
sive chemotherapy in children and adolescents with Ph-
positive ALL, a poor prognosis is still observed for some
Ph+ALL patients. The variations in the response to ther-
apy suggest that Ph+ALL is heterogeneous with regard to
sensitivity to chemotherapy, TKI and HSCT [7]. The
amount of minimal residual disease (MRD) at HSCT was
shown to be associated with the outcome of children with
ALL after HSCT [8]. In this context, serial analyses of
MRD may aid in the selection of patients who could be
treated with intensive chemotherapy protocols including a
tyrosine-kinase inhibitor.
Here, we report results of the Japanese Pediatric Leuke-
mia/Lymphoma Study Group (JPLSG) Ph+ALL04 study,
which was conducted in the same era as the COG and
EsPhALL studies. Our main objectives were to investigate
the potential therapeutic role of using imatinib immedi-
ately before HSCT and to evaluate the utility of quantita-
tive MRD assessments on EFS and OS.
Patients and Methods
Patients
Children diagnosed with untreated Ph+ALL between the
age of 1 and 18 years were consecutively enrolled from
November 2004 to May 2008 onto the JPLSG Ph+ALL04
study. Written informed consent was obtained from the
parents or guardians and from the patients as appropriate
for their age and conceptual ability.
Diagnosis of ALL was based on morphological, bio-
chemical, and flow cytometric features of leukemic cells,
including lymphoblast morphology on May- or Wright-
Giemsa-stained bone marrow smears, negative staining
for myeloperoxidase, and reactivity with monoclonal anti-
bodies to B- or T-lineage-associated lymphoid differentia-
tion antigens.
All patients with ALL were screened for diagnosis of
Ph+ALL using RT-PCR. The presence of Ph-chromosome
was further confirmed by standard karyotyping and/or
FISH analysis for BCR–ABL fusion gene. Forty-four chil-
dren with Ph+ALL were enrolled into the JPLSG
Ph+ALL04 study within 1 week of initiation of treatment
for ALL. However, two patients were not evaluable
because Ph-chromosome was not detected either with
standard karyotyping or FISH analysis; therefore, 42
patients were eligible for analysis. The median patient fol-
low-up period was 5.2 years (range: 0.6–7.5 years).
Treatment protocol
The protocol was approved by the institutional review
boards of all participating institutions and by the Clinical
Research Assessment Committee of the Japanese Society of
Pediatric Hematology, which merged with the Japan Soci-
ety of Pediatric Oncology and became the Japanese Society
of Pediatric Hematology/Oncology in January 2012.
Details of the treatment regimen of this single arm study
are outlined in Figure 1 and Table 1. Chemotherapy regi-
men was based on the high-risk arm of TCCSG (Tokyo
Children’s Cancer Study Group) L99-15 [9]. Briefly, after
five-drug induction therapy, consolidation therapy with
high-dose cytarabine with asparaginase and BFM Ib-type
was administered, followed by reinduction therapy with
four-drug. After completion of reinduction therapy, imati-
nib monotherapy phase (2 weeks of imatinib at a dose of
340 mg/m2) was started, and all patients received alloge-
neic HSCT after imatinib phase. The conditioning regimen
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of HSCT was uniform across all patients and consisted of
etoposide, cyclophosphamide, and total body irradiation
[10, 11]. Prophylactic cranial irradiation was not
employed. Imatinib was not used after HSCT. Remission
was defined as the presence of fewer than 5% blasts with
the recovery of hematopoiesis. Before and after each
phase, MRD defined as the amount of BCR–ABL tran-
scripts, was measured with the real-time PCR method
(cut-off 50 copies/lg RNA). Time points for MRD detec-
tion are shown in Figure 1.
The study was registered in UMIN-CTR (Medical
Information, University hospital Medical Information
Network—Clinical Trials Registry, URL: http://www.
umin.ac.jp/ctr/index-j.htm): UMIN ID C000000290.
Statistical analysis
The primary endpoint of this study was to examine EFS
and OS in the overall patient series and determine the
efficacy of imatinib mesylate in children with Ph+ALL
assessed by a molecular quantification technique. The
sample size was determined by the Simon’s two-stage
minimax design [12]. The lower limit of interest in the
response probability was 20% and the desirable target
level of response probability was 40%. The required sam-
ple size of eligible patients for the analysis was 33 for the
alpha error at 0.05 and beta error at 0.20. The secondary
objective was to evaluate the proportion of patients who
received HSCT in the first complete remission (CR).
The duration of EFS was defined as the time from the
initiation of therapy to either treatment failure (relapse,
death, or diagnosis of secondary cancer) or the last day
the patient was confirmed to be under remission. Patients
who did not achieve CR after the first induction phase
were considered to have failed at day 1. The probability
of EFS and OS was estimated by the Kaplan–Meier
method. All data analyses were performed using STATAⓇ
statistical software (version 11.0; StataCorp LP, College
Station, TX). Follow-up data were actualized as of 31
May 2012.
Role of the funding source
Novartis provided the study drug (imatinib mesylate).
The sponsor had no role in study design, data collection,
data analysis, data interpretation, or writing of the report.
All authors had full access to all the data in the study and
had final responsibility for decision to submit for publica-
tion.
Results
Patient characteristics and overall outcome
of patients
Of the 42 patients registered in the Ph+ALL04 study from
2004 to 2008 and included in this analysis, nine were girls
and 33 were boys and the median age at diagnosis was
7 years (range 2–15 years) (Table 2). Minor BCR–ABL
fusion gene was detected in 33 children, whereas the
major BCR–ABL fusion gene was detected in nine chil-
dren. All patients had B-cell precursor ALL. Prednisolone
Table 1. Treatment scheme of Ph+ALL04.
Induction Prednisolone 60 mg/m2 for 5 weeks, Vincristine 1.5 mg/m2 for five times, Daunorubicin 25 mg/m2 for four times,
Cyclophosphamide 1200 mg/m2 for twice, L-asparaginase 6000 U/m2 for nine times, TIT for three times
Consolidation Block 1 High-dose cytarabine (2 g/m2 for eight times) with L-asparaginase 10,000 U/m2 once, TIT once,
methylprednisolone 125 mg/m2 for eight times
Consolidation Block 2 Cyclophosphamide 1200 mg/m2 once, cytarabine 75 mg/m2 for 15 times, 6MP 60 mg/m2 for 21 days, TIT for
three times
Reinduction Dexamethasone 6 mg/m2 for 14 days, Vincristine 1.5 mg/m2 for four times, Doxorubicin 25 mg/m2 for four times,
L-asparaginase 10,000 U/m2 for four times, TIT once
Imatinib monotherapy phase Imatinib 340 mg/m2 for 14 days, TIT once
HSCT TBI 12 Gy, Etoposide 60 mg/kg (BW <30 kg) or 1800 mg/m2 (BW ≥30 kg), Cyclophosphamide 60 mg/kg for twice
TIT, triple intrathecal therapy (MTX + Ara-C + hydrocortisone). Cranial irradiation was not given. HSCT, hematopoietic stem cell transplantation.
Figure 1. Ph+ALL04 protocol and timing of MRD detection. BMA1,
day15; BMA2, day29; BMA3, before consolidation; BMA4, before
reinduction; BMA5, before imatinib mesylate; BMA6, after imatinib
mesylate; BMA7, 3 months after HSCT; BMA, bone marrow
aspiration; HSCT, hematopoietic stem cell transplantation; MRD,
minimal residual disease.
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response was assessed on day eight of steroid treatment.
Thirty-three patients (79%) had less than 1000/lL blasts
in the peripheral blood and nine patients (21%) had
equal or more than 1000/lL blasts. Of the 42 patients, 36
(86%) achieved CR and 11 of these 36 patients also
achieved MRD-negative after induction phase. A median
follow-up period was 5.4 years. The 4-year OS (Fig. 2A)
and EFS (Fig. 2B) rates among all patients were
78.1  6.5% and 54.1  7.8%, respectively.
The efficacy of imatinib monotherapy
A flow diagram of the enrolled patients is shown as Fig-
ure 3. Of 36 patients who achieved CR at the end of
induction, the effects of the imatinib monotherapy phase
was evaluable in 30 patients, as six patients excluded due
to relapse (n = 1), transferring to non-JPLSG hospital
(n = 2), and withdrawal (n = 3). There were 13 patients
who had no MRD at the beginning of this phase, all of
whom remained MRD-negative after imatinib monothera-
py with the exception of one patient who had 100 copies/
lg RNA of BCR–ABL transcripts after 2 weeks of imati-
nib monotherapy. There were five patients who showed
clearance of BCR–ABL transcripts after imatinib: the copy
number of transcripts/lg RNA of these patients was 450,
280, 250, 130, and 77, respectively. In the remaining 12
patients, three showed decrease of more than 1  log
transcripts: from 6600 to 140, from 39,000 to 1700, and
from 1500 to 76, whereas four patients relapsed after this
phase. Imatinib was well tolerated in all the patients.
HSCT in the first CR
After 2-weeks of imatinib monotherapy, 26 patients
underwent HSCT in the first CR, including 17 patients
who were MRD-negative at the time of HSCT (Fig. 2).
The grafts were bone marrow from related donors for 10
patients, unrelated bone marrow for 10 patients, related
cord blood for 1 patient, and unrelated cord blood for
five patients. All the patients achieved engraftment, and
no patients died because of complications of HSCT.
Five patients relapsed, all of whom were MRD negative
before HSCT, Only two of the patients are alive after the
second HSCT whereas the other three patients died
because of treatment-related mortality. Twenty-one
patients continued to be in 1st CR and MRD-negative for
a median of 5.2 years after diagnosis. Of note, all the five
patients who were treated with unrelated cord blood
transplantation continued to be in 1st CR.
Outcome of patients who did not have CR
or who relapsed before HSCT
Of six patients who suffered induction failure, five
patients were switched to an imatinib-containing chemo-
therapy treatment. Four of the five patients achieved CR,
Table 2. Characteristics of children with Ph+ALL (n = 42).
Median age at diagnosis (range) 7 years (2–15 years)
Girls/boys 9/33
White blood cell at diagnosis
(range)
39 9 109/L (1  681 9 109/L)
CNS involvement at diagnosis
yes1/no
3/39
Minor BCR–ABL/major BCR–ABL 33/9
Prednisolone response
PGR2/PPR3 33/9
4-year EFS 54.1  7.8%
4-year OS 78.1  6.5%
1CNS involvement was observed in three patients: all the three
patients had blasts in the CSF.
2PGR, prednisolone good responder (less than 1000/lL blasts in the
peripheral blood after 7 days of prednisolone treatment).
3PPR, prednisolone poor responder (equal or more than 1000/lL
blasts in the peripheral blood after 7 days of prednisolone treatment).
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Figure 2. Overall survival of children with Ph+ALL (n = 42) (A) and event-free survival of children with Ph+ALL (n = 42) (B).
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and all of these four patients received cord blood trans-
plantation and remain in continued CR at 36, 42, 44, and
61 months after HSCT. Five patients relapsed before
HSCT: one after consolidation and four after imatinib
therapy. Three of the five patients achieved CR after
imatinib-containing chemotherapy, and two of them are
alive at 49 and 54 months after HSCT.
Discussion
Addition of new drugs to conventional chemotherapy reg-
imens is a challenging issue in treatment of leukemia.
During the planning phase of the study, imatinib was not
being used in children with Ph+ALL. The amount of
MRD at HSCT was reported in relation to outcomes of
children with ALL after HSCT [8]. Therefore, we tested
the hypothesis that the use of imatinib immediately
before HSCT might be beneficial for children with
Ph+ALL since it may reduce the amount of MRD at
HSCT. We also measured BCR–ABL transcripts as a bio-
marker for imatinib response, to clarify its effect even
when the disease was in CR. In this study, the chemother-
apy regimen we employed was based on the previous
high-risk treatment protocol of the TCCSG L-99-15 Study
[9]. The treatment strategy was effective in inducing
MRD-negative status in 13 patients at the time of the
imatinib phase and 26 of 42 patients (62%) achieved first
CR at the time of HSCT (around 25–28 weeks after diag-
nosis). In consequence, it was not possible to perform a
robust assessment of the efficacy of imatinib because the
number of patients with detectable MRD (n = 17) at the
beginning of the imatinib phase was much smaller than
expected. Nevertheless, the imatinib therapy appeared to
have antileukemic effects indicated by the observation
that 47% of patients with detectable MRD at the begin-
ning of this phase transitioned to MRD negative status
after the short course imatinib treatment.
Twenty-six patients received HSCT in the first CR.
Among them, MRD was negative at HSCT in 17 patient
and all the five patients who relapsed after HSCT were
MRD-negative at HSCT. In contrast, relapse was not
observed in nine patients with a detectable level of MRD
at HSCT. This suggests that the detection of MRD at
HSCT was not related to the occurrence of relapse after
HSCT in children with Ph+ALL. In adults with Ph+ALL,
Lee et al. also described that the level of MRD at HSCT
had little association with relapse after HSCT [13]. How-
ever, in the Japan Adult Leukemia Study Group (JALSG)
Ph+ALL202 protocol, the relapse rate was significantly
lower among patients who were MRD negative at HSCT
[14]. More sensitive techniques, such as a deep-sequenc-
ing approach, may help to elucidate the significance of
MRD at HSCT in patients with Ph+ALL [15].
The amount of MRD at the early phase of treatment
for children with ALL distinguishes patients with good
prognoses from those with poor prognoses [16, 17]. In
our study, the amounts of BCR–ABL transcripts were
prospectively monitored. In our cohort, among 26
patients who received HSCT at the first CR, 11 had
MRD-negativity at the end of induction therapy, and two
of the 11 patients relapsed after HSCT, while three of 15
patients with MRD-positivity at the end of induction suf-
fered relapse after HSCT. Although the number of
patients is small, the high/low status of MRD at the end
of induction therapy did not seem to be correlated
with relapse after HSCT. However, these data should be
Figure 3. Flow diagram and MRD status of patients. MRD, minimal residual disease.
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interpreted with caution because the method to detect
MRD in our study and in JALSG was PCR detection of
BCR–ABL transcripts, not an immunoglobulin/T-cell
receptor (Ig/TCR) DNA-based technique or flow cytome-
try. In fact, Jeha, et al. recently reported that MRD
detected with flow cytometry at the end of induction was
dramatically reduced when TKI was incorporated into
induction regimens [18].
In contrast, five of six patients who relapsed before
HSCT had a high level of MRD of more than 10,000 cop-
ies/lg RNA of BCR–ABL at least 1 month before hemato-
logical relapse. Zaliova, et al. also reported BCR–ABL
transcript-based MRD enabled better and earlier predic-
tion of relapse compared to DNA-based MRD [19].
Taken together, the value of BCR–ABL-transcript-based-
MRD has not yet been fully defined. Prospective studies
in Ph+ALL patients comparing several methods of MRD
assessment including BCR–ABL transcript, Ig/TCR-DNA,
and flow cytometry is warranted. Although response to
treatment based on MRD is considered essential for risk
group stratification in current protocols for childhood
ALL, the innate characteristics of leukemic cells, including
additional karyotypic abnormalities[5] and deletion of
IKZF-1 [20], might also be informative for the prediction
of outcomes in patients with Ph+ALL.
Although OS was excellent in this study, an 86%
induction rate appears unsatisfactory, in addition to six
out of 36 patients in CR after induction phase experienc-
ing a relapse before HSCT. The use of imatinib in the
earlier phase of treatment, even in the induction phase,
may be beneficial in children with Ph+ALL. Indeed, imati-
nib has been used in the induction phase of adult trials
and has demonstrated an increase in CR rate [21]. Fur-
thermore, imatinib was successfully used in children from
day 15 of induction in a recent SHOP study from Spain,
but results were based on a small number of patients
(n = 16) [22]. In our study, all the nine patients treated
with imatinib-containing chemotherapy as a salvage ther-
apy achieved CR. Hyper-CVAD with imatinib was
employed in seven of these nine patients. Hyper-CVAD
with imatinib, which is widely used for adults with
Ph+ALL [23], may be an alternative option for children
with Ph+ALL as a salvage therapy. Detailed clinical course
of these patients will be reported separately.
Both the COG and EsPhALL studies, which were con-
temporary to our study, showed that the use of imatinib
concurrently with standard chemotherapy for ALL was safe
and tolerable. Conceivably, HSCT may be omitted in a sub-
set of patients who achieve deep remission status if earlier
and longer use of imatinib is applied. In our study, all nine
patients who were in first CR with a detectable level of
MRD at HSCT continue to be in the first CR with negative
MRD after HSCT. Based on our data, HSCT itself was safe
and effective for children with Ph+ALL. Among 26 patients
who were transplanted, no patients experienced treatment-
related mortality in spite of the use of unrelated grafts in
more than half of patients. It might be due to a uniform
use of preconditioning regimen, a good selection of donors
and an appropriate timing of HSCT. Eckert et al. also
described the importance of standardization of HSCT pro-
cedure in the ALL REZ BFM 2002 trial [17]. Since the late
effects of HSCT are substantial, the indication of HSCT
should be limited. However, HSCT is still an important
modality for patients who are at high-risk for relapse, and
conditioning regimen consisting of TBI, VP and CY may
become a standard regimen for HSCT.
In conclusion, we interpret our results to suggest that
the brief use of imatinib monotherapy on leukemic cells
prior to HSCT may have a potential therapeutic effect
which was demonstrated by 47% of MRD-positive patients
transitioning to MRD negative status by the end of this
phase. In addition, this was the first prospective trial to
conduct HSCT in all children with Ph+ALL in first CR with
a uniform conditioning treatment. Use of this protocol
achieved an OS of approximately 80%. This result could
serve as a basis for future trials aiming to reduce the rate of
children who need be treated without HSCT. Finally
prospective studies of Ph+ALL are warranted for the com-
parison of various MRD assessment methods, including
BCR–ABL transcript, Ig/TCR-DNA and flow cytometry.
Acknowledgments
We thank Tomoyuki Watanabe for statistical assistance,
Emiko Nishioka for preparing and refining the data of
patients and Kevin Urayama for editing the manuscript.
We also thank the members of the Ph+ALL Committee of
the JPLSG: Soichi Adachi, Kazuko Hamamoto, Makoto
Yoshida, Keiko Yagi, Akira Ohara, Koichiro Ikuta, Masa-
hiro Tsuchida, Hiroyuki Takahashi, Atsushi Kikuta, Arata
Watanabe, Motoaki Chin, Tsutomu Watanabe, Michiko
Kajiwara, and Tetsuya Takimoto. Finally, we thank all
pediatricians and nurses who participated in the treat-
ment and follow-up of patients in this study. This study
was supported by a grant from the Ministry of Health,
Labour and Welfare and a grant from the Children’s Can-




1. Pui, C. H., M. V. Relling, and J. R. Downing. 2004. Acute
lymphoblastic leukemia. N. Engl. J. Med. 350:1535–1548.
ª 2015 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. 687
A. Manabe et al. Brief Imatinib in Children with Ph+ALL
2. Inaba, H., M. Greaves, and C. G. Mullighan. 2013. Acute
lymphoblastic leukaemia. Lancet 381:1943–1955.
3. Arico, M., M. Schrappe, S. P. Hunger, W. L. Carroll, V.
Conter, S. Galimberti, et al. 2010. Clinical outcome of
children with newly diagnosed Philadelphia chromosome-
positive acute lymphoblastic leukemia treated between
1995 and 2005. J. Clin. Oncol. 28:4755–4761.
4. Schultz, K. R., W. P. Bowman, A. Aledo, W. B. Slayton,
H. Sather, M. Devidas, et al. 2009. Improved early
event-free survival with imatinib in Philadelphia
chromosome-positive acute lymphoblastic leukemia: a
children’s oncology group study. J. Clin. Oncol.
27:5175–5181.
5. Schultz, K. R., A. Carroll, N. A. Heerema, W. P. Bowman,
A. Aledo, W. B. Slayton, et al. 2014. Long-term follow-up
of imatinib in pediatric Philadelphia chromosome-positive
acute lymphoblastic leukemia: Children’s Oncology Group
Study AALL0031. Leukemia 28:1467–1471.
6. Biondi, A., M. Schrappe, P. De Lorenzo, A. Castor, G.
Lucchini, V. Gandemer, et al. 2012. Imatinib after
induction for treatment of children and adolescents with
Philadelphia-chromosome-positive acute lymphoblastic
leukaemia (EsPhALL): a randomised, open-label,
intergroup study. Lancet Oncol. 13:936–945.
7. Druker, B. J., C. L. Sawyers, H. Kantarjian, D. J. Resta, S.
F. Reese, J. M. Ford, et al. 2001. Activity of a specific
inhibitor of the BCR-ABL tyrosine kinase in the blast crisis
of chronic myeloid leukemia and acute lymphoblastic
leukemia with the Philadelphia chromosome. N. Engl. J.
Med. 344:1038–1042.
8. Leung, W., C. H. Pui, E. Coustan-Smith, J. Yang, D. Pei,
K. Gan, et al. 2012. Detectable minimal residual disease
before hematopoietic cell transplantation is prognostic but
does not preclude cure for children with very-high-risk
leukemia. Blood 120:468–472.
9. Manabe, A., A. Ohara, D. Hasegawa, K. Koh, T. Saito, N.
Kiyokawa, et al. 2008. Significance of the complete
clearance of peripheral blasts after 7 days of prednisolone
treatment in children with acute lymphoblastic leukemia:
the Tokyo Children’s Cancer Study Group Study L99-15.
Haematologica 93:1155–1160.
10. Yabe H., on behalf of the Stem Cell Transplantation
Committee of Tokyo Children’s Cancer Study Group
(TCCSG). 2011. Intensified conditioning with total-body
irradiation, etoposide and cyclophosphamide for children
with acute lymphoblastic leukemia in first and second
complete remission. Bone Marrow Transplant. 46(Suppl.):
s270.
11. Bunin, N., R. Aplenc, N. Kamani, K. Shaw, A. Cnaan, and
S. Simms. 2003. Randomized trial of busulfan vs total
body irradiation containing conditioning regimens for
children with acute lymphoblastic leukemia: a Pediatric
Blood and Marrow Transplant Consortium study. Bone
Marrow Transplant. 32:543–548.
12. Simon, R. 1989. Optimal two-stage designs for phase II
clinical traials. Control. Clin. Trials 10:1–10.
13. Lee, S., Y. J. Kim, N. G. Chung, J. Lim, D. G. Lee, H. J.
Kim, et al. 2009. The extent of minimal residual disease
reduction after the first 4-week imatinib therapy
determines outcome of allogeneic stem cell transplantation
in adults with Philadelphia chromosome-positive acute
lymphoblastic leukemia. Cancer 115:561–570.
14. Mizuta, S., K. Matsuo, F. Yagasaki, T. Yujiri, Y. Hatta, Y.
Kimura, et al. 2011. Pre-transplant imatinib-based therapy
improves the outcome of allogeneic hematopoietic stem
cell transplantation for BCR-ABL-positive acute
lymphoblastic leukemia. Leukemia 25:41–47.
15. Soverini, S., C. De Benedittis, K. Machova Polakova, A.
Brouckova, D. Horner, M. Iacono, et al. 2013. Unraveling
the complexity of tyrosine kinase inhibitor-resistant
populations by ultra-deep sequencing of the BCR-ABL
kinase domain. Blood 122:1634–1648.
16. van Dongen, J. J., T. Seriu, E. R. Panzer-Grumayer, A.
Biondi, M. J. Pongers-Willemse, L. Corral, et al. 1998.
Prognostic value of minimal residual disease in acute
lymphoblastic leukaemia in childhood. Lancet 352:1731–
1738.
17. Eckert, C., G. Henze, K. Seeger, N. Hagedorn, G. Mann, R.
Panzer-Grumayer, et al. 2013. Use of allogeneic
hematopoietic stem-cell transplantation based on minimal
residual disease response improves outcomes for children
with relapsed acute lymphoblastic leukemia in the
intermediate-risk group. J. Clin. Oncol. 31:2736–2742.
18. Jeha, S., E. Coustan-Smith, D. Pei, J. T. Sandlund, J. E.
Rubnitz, S. C. Howard, et al. 2014. Impact of tyrosine
kinase inhibitors on minimal residual disease and outcome
in childhood Philadelphia chromosome-positive acute
lymphoblastic leukemia. Cancer 120:1514–1519.
19. Zaliova, M., E. Fronkova, K. Krejcikova, K. Muzikova, E.
Majstrikova, J. Stary, et al. 2009. Quantification of fusion
transcript reveals a subgroup with distinct biological
properties and predicts relapse in BCR/ABL-positive ALL:
implications for residual disease monitoring. Leukemia
23:944–951.
20. van der Veer, A., M. Zaliova, F. Mottadelli, P. De Lorenzo,
G. Te Kronnie, C. J. Harrison, et al. 2014. IKZF1 status as
a prognostic feature in BCR-ABL1-positive childhood ALL.
Blood 123:1691–1698.
21. Towatari, M., M. Yanada, N. Usui, J. Takeuchi, I. Sugiura,
M. Takeuchi, et al. 2004. Combination of intensive
chemotherapy and imatinib can rapidly induce high-
quality complete remission for a majority of patients with
newly diagnosed BCR-ABL-positive acute lymphoblastic
leukemia. Blood 104:3507–3512.
22. Rives, S., J. Estella, P. Gomez, M. Lopez-Duarte, P. G. de
Miguel, et al. 2011. Intermediate dose of imatinib in
combination with chemotherapy followed by allogeneic
stem cell transplantation improves early outcome in
688 ª 2015 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
Brief Imatinib in Children with Ph+ALL A. Manabe et al.
paediatric Philadelphia chromosome-positive acute
lymphoblastic leukaemia (ALL): results of the Spanish
Cooperative Group SHOP studies ALL-94, ALL-99 and
ALL-2005. Br. J. Haematol. 154:600–611.
23. Thomas, D. A., S. Faderl, J. Cortes, S. O’Brien, F. J. Giles,
S. M. Kornblau, et al. 2004. Treatment of Philadelphia
chromosome-positive acute lymphocytic leukemia with
hyper-CVAD and imatinib mesylate. Blood 103:4396–4407.
Supporting Information
Additional Supporting Information may be found in the
online version of this article:
Figure S1. Kinetics of MRD during treatment. Each dot
indicates each patient. Time points are shown in Figure 1.
MRD, minimal residual disease.
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